MedPath

HEPTARES THERAPEUTICS LIMITED

πŸ‡ΊπŸ‡ΈUnited States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

11

Active:0
Completed:10

Trial Phases

2 Phases

Phase 1:10
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (11 trials with phase data)β€’ Click on a phase to view related trials

Phase 1
10 (90.9%)
Phase 2
1 (9.1%)

Measurement of HTL0016878 in Cerebrospinal Fluid

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
First Posted Date
2021-04-19
Last Posted Date
2021-04-19
Lead Sponsor
Heptares Therapeutics Limited
Target Recruit Count
16
Registration Number
NCT04849286
Locations
πŸ‡¬πŸ‡§

MAC Clinical Research, Manchester, United Kingdom

Study to Investigate the Receptor Occupancy of HTL0014242 Using [18F] FPEB in Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2020-07-08
Last Posted Date
2021-07-07
Lead Sponsor
Heptares Therapeutics Limited
Target Recruit Count
8
Registration Number
NCT04462263
Locations
πŸ‡¬πŸ‡§

Parexel Early Phase Clinical Unit, Harrow, Middlesex, United Kingdom

Phase 1, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of mGlu5 NAM HTL0014242

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo oral capsule
First Posted Date
2018-12-24
Last Posted Date
2021-04-29
Lead Sponsor
Heptares Therapeutics Limited
Target Recruit Count
71
Registration Number
NCT03785054
Locations
πŸ‡¬πŸ‡§

Covance, Leeds, West Yorkshire, United Kingdom

A Study to Assess Safety, Tolerability, and Efficacy of HTL0018318 in Patients With Dementia With Lewy Bodies

Phase 2
Withdrawn
Conditions
Dementia With Lewy Bodies
Interventions
Drug: Placebo
First Posted Date
2018-07-19
Last Posted Date
2019-10-01
Lead Sponsor
Heptares Therapeutics Limited
Registration Number
NCT03592862
Locations
πŸ‡―πŸ‡΅

Nishitaga Hospital, Sendai, Japan

πŸ‡―πŸ‡΅

Kagawa Prefectural Central Hospital, Takamatsu, Japan

πŸ‡―πŸ‡΅

Kurumi Clinic, Tokyo, Japan

Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care

Phase 1
Completed
Conditions
Alzheimer's Disease
Interventions
Drug: Placebo
First Posted Date
2018-03-07
Last Posted Date
2018-07-20
Lead Sponsor
Heptares Therapeutics Limited
Target Recruit Count
60
Registration Number
NCT03456349
Locations
πŸ‡ͺπŸ‡Έ

Syneos, Barcelona, Spain

  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.